Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 193
interventional 175
Observational 17
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 106
Drug|Other 16
Drug|placebo 7
Biological|Drug|Procedure|Radiation 5
Drug|Other|Procedure|Radiation 5
Biological|Other 4
Drug|Procedure 4
Drug|Other|Procedure 3
Behavioral|Drug 2
Biological 2
Drug|Procedure|Radiation 2
Other|Procedure 2
Procedure 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|Procedure 1
Biological|Drug|Other|Procedure|Radiation 1
Biological|Drug|Procedure 1
Biological|Drug|Radiation 1
Biological|Procedure 1
Device 1
Diagnostic Test 1
Dietary Supplement|Drug 1
Drug|Genetic|Other|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Other 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 100
United States|Canada 6
United States|Australia|Canada 4
France 3
Germany 3
China 2
Denmark 2
Japan 2
NA 2
United States|Italy 2
Algeria|Argentina|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Germany|Greece|Hungary|Ireland|Israel|Italy|Mexico|Morocco|Poland|Portugal|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Thailand|Tunisia 1
Australia|Austria|Belgium|China|Czechia|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Bulgaria|Chile|China|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Portugal|Russian Federation|South Africa|Spain|Sweden|Thailand|Turkey 1
Australia|Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Spain|United Kingdom 1
Australia|Belgium|Denmark|Germany|Hungary|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
Australia|Belgium|France|Germany|Israel|Spain 1
Australia|Canada|France|Germany|Italy|Netherlands|Singapore|United Kingdom 1
Austria|Belgium|Bulgaria|Canada|Germany|Greece|Italy|Japan|Russian Federation|Spain|Turkey 1
Austria|Belgium|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Belgium|Netherlands 1
Canada 1
China|Japan|Korea, Republic of|Taiwan 1
France|Germany|Ireland|Italy|United Kingdom 1
Germany|Moldova, Republic of 1
Germany|Moldova, Republic of|Romania 1
Israel 1
Italy 1
Japan|United States|Australia|Austria|Belgium|Canada|China|France|Germany|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Qatar 1
Russian Federation 1
Switzerland 1
United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Lithuania|Mexico|Poland|Portugal|Romania|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|France|Germany|Greece|Israel|Italy|Lebanon|Malaysia|Netherlands|Spain|Sweden|Taiwan|Thailand|Tunisia|Turkey|United Kingdom 1
United States|Australia|Canada|France|Germany 1
United States|Australia|Canada|Italy|Japan|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Canada|New Zealand|Saudi Arabia 1
United States|Australia|Germany|Italy|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Austria|China|France|Germany|Italy|Netherlands|United Kingdom 1
United States|Austria|Italy|Spain|United Kingdom 1
United States|Austria|Netherlands 1
United States|Belarus|Canada|Czechia|France|Georgia|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Belgium|Canada|France|Germany|Israel|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Belgium|Canada|Germany|Greece|Italy|Netherlands|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Canada|Czechia|France|Germany|Hungary|Poland|Spain|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Netherlands|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Spain|United Kingdom 1
United States|Canada|Germany|Italy 1
United States|Canada|Italy|Sweden 1
United States|Canada|New Zealand 1
United States|France 1
United States|France|Italy|United Kingdom 1
United States|France|United Kingdom 1
United States|Korea, Republic of 1

Sites per Study

Site_count Study_Count
1 79
2 14
3 8
4 2
5 5
6 7
7 4
8 2
9 5
10 4
11 3
12 1
13 2
14 1
16 1
17 3
18 2
20 1
21 3
22 2
23 1
24 1
26 2
29 1
30 1
35 1
38 1
42 1
48 2
61 1
65 1
67 1
72 1
76 1
87 1
96 1
101 1
104 1
112 1
114 1
123 1
124 1
141 1
273 1

Phase

Phase Study_Count
Phase 2 86
Phase 1 37
Phase 1/Phase 2 18
Phase 3 17
N/A 11
Early Phase 1 3
Phase 4 2
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 111
2 28
3 13
4 8
5 6
6 3
10 1
NA 5

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 12.0 5.00000 10.00000 9.00000 5.00000 39 51.0000 48
1st Qu. 13.5 20.50000 24.00000 40.50000 27.00000 39 192.0000 125
Median 15.0 62.00000 36.00000 58.00000 49.00000 39 267.0000 202
Mean 16.0 81.63636 38.86486 78.27778 64.04706 39 523.5882 202
3rd Qu. 18.0 115.00000 59.00000 86.75000 87.00000 39 432.0000 279
Max. 21.0 222.00000 80.00000 271.00000 400.00000 39 2233.0000 356

Trial Group Type

group_type Group_Count
Experimental 254
Active Comparator 25
Other 11
NA 5
Placebo Comparator 3
No Intervention 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 117
Parallel Assignment 48
Crossover Assignment 3
Sequential Assignment 3
NA 3
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 155
Supportive Care 11
Other 4
Diagnostic 2
Prevention 2
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 6
France 2
Italy 2
NA 2
United States|Italy 2
Italy|Spain|Sweden 1
United States|Canada|Italy|United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 7
2 1
4 1
6 2
11 1
12 2
20 1
22 1
116 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 62.0000
Median 153.0000
Mean 426.1765
3rd Qu 650.0000
Max 1500.0000

Observation Model

observational_model Study_Count
Cohort 9
NA 3
Other 2
Case-Control 1
Case-Only 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 6
Other 5
Retrospective 3
NA 2
Cross-Sectional 1

Registries

Studies by Country

Country Study_Count
Canada 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 5000
1st Qu 5000
Median 5000
Mean 5000
3rd Qu 5000
Max 5000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Other 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04173494 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) https://ClinicalTrials.gov/show/NCT04173494 Recruiting Sierra Oncology, Inc. 2021-12-31
NCT04097821 Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT04097821 Recruiting Novartis 2024-01-16
NCT03912064 A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT https://ClinicalTrials.gov/show/NCT03912064 Recruiting Dana-Farber Cancer Institute 2022-04-26
NCT03402399 Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis https://ClinicalTrials.gov/show/NCT03402399 Recruiting Assaf-Harofeh Medical Center 2019-12-09
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis https://ClinicalTrials.gov/show/NCT03373877 Active, not recruiting Samus Therapeutics, Inc. 2020-10-31
NCT03333187 Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability https://ClinicalTrials.gov/show/NCT03333187 Recruiting Universitätsklinikum Hamburg-Eppendorf 2021-03-31
NCT03326310 Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia https://ClinicalTrials.gov/show/NCT03326310 Recruiting University of Chicago 2021-09-04
NCT03194542 A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence https://ClinicalTrials.gov/show/NCT03194542 Recruiting Celgene 2021-06-16
NCT03144687 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT03144687 Active, not recruiting Incyte Corporation 2020-07-31
NCT03136185 IMG-7289 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT03136185 Recruiting Imago BioSciences,Inc. 2020-12-31
NCT03118492 Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis https://ClinicalTrials.gov/show/NCT03118492 Recruiting City of Hope Medical Center 2021-05-24
NCT03116542 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03116542 Recruiting Hamad Medical Corporation 2020-05-31
NCT03069326 A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT03069326 Recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT03065400 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03065400 Completed Icahn School of Medicine at Mount Sinai 2020-05-28
NCT03018223 Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT https://ClinicalTrials.gov/show/NCT03018223 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2018-12-15
NCT02966353 Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. https://ClinicalTrials.gov/show/NCT02966353 Completed Novartis 2018-07-24
NCT02917096 Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02917096 Active, not recruiting City of Hope Medical Center 2020-10-05
NCT02807077 PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects https://ClinicalTrials.gov/show/NCT02807077 Completed CTI BioPharma 2015-07-31
NCT02806375 PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis https://ClinicalTrials.gov/show/NCT02806375 Completed St. Petersburg State Pavlov Medical University 2018-12-31
NCT02784496 Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02784496 Active, not recruiting M.D. Anderson Cancer Center 2024-09-30
NCT02765724 Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects https://ClinicalTrials.gov/show/NCT02765724 Completed CTI BioPharma 2015-06-30
NCT02742324 Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg https://ClinicalTrials.gov/show/NCT02742324 Recruiting French Innovative Leukemia Organisation 2020-12-31
NCT02730884 Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia https://ClinicalTrials.gov/show/NCT02730884 Completed M.D. Anderson Cancer Center 2019-08-22
NCT02718300 A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT02718300 Recruiting Incyte Corporation 2021-01-31
NCT02660281 URMC Related Haplo-identical Donor BMT https://ClinicalTrials.gov/show/NCT02660281 Recruiting University of Rochester 2025-10-31
NCT02593760 A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) https://ClinicalTrials.gov/show/NCT02593760 Completed Hoffmann-La Roche 2017-03-29
NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT03165734 Recruiting CTI BioPharma 2022-07-31
NCT01433445 Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis https://ClinicalTrials.gov/show/NCT01433445 Completed Novartis 2020-06-22
NCT02515630 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) https://ClinicalTrials.gov/show/NCT02515630 Completed Sierra Oncology, Inc. 2017-07-18
NCT02493530 TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea https://ClinicalTrials.gov/show/NCT02493530 Active, not recruiting Vanderbilt-Ingram Cancer Center 2020-12-31
NCT02436135 Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease https://ClinicalTrials.gov/show/NCT02436135 Completed Gilead Sciences 2017-11-20
NCT02426086 Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor https://ClinicalTrials.gov/show/NCT02426086 Completed Geron Corporation 2018-04-26
NCT02386800 CINC424A2X01B Rollover Protocol https://ClinicalTrials.gov/show/NCT02386800 Recruiting Novartis 2025-09-17
NCT02370706 Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02370706 Active, not recruiting Novartis 2020-09-02
NCT02370329 P1101 in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02370329 Recruiting Mayo Clinic 2020-03-31
NCT03386214 Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT03386214 Recruiting Washington University School of Medicine 2021-05-31
NCT02311569 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation https://ClinicalTrials.gov/show/NCT02311569 Completed Swiss Group for Clinical Cancer Research 2016-12-31
NCT02268253 Tagraxofusp (SL-401) in Patients With CMML or MF https://ClinicalTrials.gov/show/NCT02268253 Recruiting Stemline Therapeutics, Inc. 2021-07-31
NCT02267278 Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) https://ClinicalTrials.gov/show/NCT02267278 Completed M.D. Anderson Cancer Center 2018-06-01
NCT02251821 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis https://ClinicalTrials.gov/show/NCT02251821 Recruiting Fred Hutchinson Cancer Research Center 2021-03-11
NCT02167958 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source https://ClinicalTrials.gov/show/NCT02167958 Completed University of Pittsburgh 2019-09-21
NCT02158858 A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02158858 Recruiting Constellation Pharmaceuticals 2021-08-31
NCT02129101 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies https://ClinicalTrials.gov/show/NCT02129101 Completed Mayo Clinic 2016-12-31
NCT02124746 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02124746 Completed Sierra Oncology, Inc. 2018-12-06
NCT02101268 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT02101268 Completed Sierra Oncology, Inc. 2016-07-28
NCT02098161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis https://ClinicalTrials.gov/show/NCT02098161 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT02087059 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis https://ClinicalTrials.gov/show/NCT02087059 Completed Novartis 2015-03-31
NCT02065154 Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis https://ClinicalTrials.gov/show/NCT02065154 Active, not recruiting University of Alabama at Birmingham 2020-04-30
NCT01317875 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) https://ClinicalTrials.gov/show/NCT01317875 Active, not recruiting Incyte Corporation 2020-09-30
NCT01290302 Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01290302 Completed American Regent, Inc. 2012-12-31
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT01369498 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01369498 Completed Gilead Sciences 2014-06-05
NCT01981850 A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01981850 Active, not recruiting Promedior, Inc. 2017-08-30
NCT01969838 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01969838 Completed Sierra Oncology, Inc. 2016-09-12
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01814475 Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis https://ClinicalTrials.gov/show/NCT01814475 Completed Gruppo Italiano Trapianto di Midollo Osseo 2016-12-31
NCT01795677 JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01795677 Active, not recruiting French Innovative Leukemia Organisation 2018-05-31
NCT01787552 A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF https://ClinicalTrials.gov/show/NCT01787552 Completed Novartis 2018-04-10
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01732445 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01732445 Completed Mayo Clinic 2016-07-14
NCT01731951 Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis https://ClinicalTrials.gov/show/NCT01731951 Completed Geron Corporation 2018-05-24
NCT01712308 Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia https://ClinicalTrials.gov/show/NCT01712308 Recruiting M.D. Anderson Cancer Center 2020-02-28
NCT01693601 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) https://ClinicalTrials.gov/show/NCT01693601 Completed Icahn School of Medicine at Mount Sinai 2018-05-18
NCT01692366 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly https://ClinicalTrials.gov/show/NCT01692366 Completed Sanofi 2014-03-31
NCT01644110 Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF https://ClinicalTrials.gov/show/NCT01644110 Recruiting University of Ulm 2022-05-31
NCT01633372 An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01633372 Active, not recruiting Incyte Corporation 2013-12-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01558739 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) https://ClinicalTrials.gov/show/NCT01558739 Completed Novartis 2014-01-31
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523171 Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT01523171 Completed Sanofi 2014-04-30
NCT01499147 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01499147 Completed University of Illinois at Chicago 2013-05-31
NCT01493414 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. https://ClinicalTrials.gov/show/NCT01493414 Completed Novartis 2017-01-26
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01445769 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01445769 Completed Incyte Corporation 2013-03-31
NCT01437787 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01437787 Completed Sanofi 2014-06-30
NCT01428635 Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy https://ClinicalTrials.gov/show/NCT01428635 Active, not recruiting M.D. Anderson Cancer Center 2020-01-31
NCT01423851 Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT01423851 Active, not recruiting NS Pharma, Inc. 2020-11-30
NCT01420770 Phase 2 Study of SAR302503 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01420770 Completed Sanofi 2014-04-30
NCT01398462 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT01398462 Completed JW Pharmaceutical 2015-12-31
NCT01392443 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF https://ClinicalTrials.gov/show/NCT01392443 Completed Novartis 2017-10-31
NCT01387763 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT01387763 Active, not recruiting Odense University Hospital 2020-01-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01375140 Ruxolitinib and Lenalidomide for Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01375140 Completed M.D. Anderson Cancer Center 2018-09-05
NCT01371617 A Phase 2 Study With IPI-926 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01371617 Completed Infinity Pharmaceuticals, Inc. 2012-08-31
NCT01348490 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) https://ClinicalTrials.gov/show/NCT01348490 Completed Incyte Corporation 2018-12-19
NCT01340651 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT01340651 Completed Incyte Corporation 2012-07-31
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT04282187 Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04282187 Recruiting University of Washington 2024-11-11
NCT04217993 Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis https://ClinicalTrials.gov/show/NCT04217993 Recruiting Suzhou Zelgen Biopharmaceuticals Co.,Ltd 2021-04-18
NCT04176198 A Study of Oral TP-3654 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT04176198 Recruiting Boston Biomedical, Inc 2022-03-31
NCT04064060 A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials https://ClinicalTrials.gov/show/NCT04064060 Recruiting Celgene 2028-01-24
NCT03952039 An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03952039 Recruiting Celgene 2021-11-24
NCT03895112 MPN-RC 118 AVID200 in Myelofibrosis https://ClinicalTrials.gov/show/NCT03895112 Recruiting Icahn School of Medicine at Mount Sinai 2021-03-31
NCT03886415 Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis. https://ClinicalTrials.gov/show/NCT03886415 Recruiting Suzhou Zelgen Biopharmaceuticals Co.,Ltd 2021-02-01
NCT03869476 Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. https://ClinicalTrials.gov/show/NCT03869476 Recruiting University Hospital, Angers 2023-06-30
NCT03862157 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03862157 Recruiting M.D. Anderson Cancer Center 2024-01-01
NCT03755518 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03755518 Recruiting Celgene 2022-05-19
NCT03662126 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor https://ClinicalTrials.gov/show/NCT03662126 Recruiting Kartos Therapeutics, Inc. 2021-08-01
NCT03645824 Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) https://ClinicalTrials.gov/show/NCT03645824 Recruiting Stichting Hemato-Oncologie voor Volwassenen Nederland 2022-09-30
NCT03627403 Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors https://ClinicalTrials.gov/show/NCT03627403 Recruiting University of Utah 2024-03-14
NCT03566446 CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03566446 Active, not recruiting Herlev Hospital 2020-02-20
NCT03441113 Extended Access of Momelotinib in Adults With Myelofibrosis https://ClinicalTrials.gov/show/NCT03441113 Enrolling by invitation Sierra Oncology, Inc. 2024-12-31
NCT03427866 Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. https://ClinicalTrials.gov/show/NCT03427866 Recruiting Massachusetts General Hospital 2021-09-30
NCT03426969 Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis https://ClinicalTrials.gov/show/NCT03426969 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT01236638 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01236638 Completed Sierra Oncology, Inc. 2014-06-30
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01200498 Study of SB939 in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01200498 Completed M.D. Anderson Cancer Center 2012-11-30
NCT01178281 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence https://ClinicalTrials.gov/show/NCT01178281 Completed Celgene 2013-01-01
NCT01149681 Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis https://ClinicalTrials.gov/show/NCT01149681 Completed PharmaMar 2011-02-28
NCT01134120 A Study in Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT01134120 Completed Eli Lilly and Company 2014-04-30
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00997386 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States https://ClinicalTrials.gov/show/NCT00997386 Completed University of Arizona 2014-04-30
NCT00952289 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial https://ClinicalTrials.gov/show/NCT00952289 Completed Incyte Corporation 2010-11-30
NCT00946270 Pomalidomide for Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT00946270 Completed M.D. Anderson Cancer Center 2018-05-22
NCT00935987 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT00935987 Completed Sierra Oncology, Inc. 2012-04-30
NCT00934544 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial https://ClinicalTrials.gov/show/NCT00934544 Completed Novartis 2015-03-04
NCT00931762 Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis https://ClinicalTrials.gov/show/NCT00931762 Completed Novartis 2011-08-31
NCT00910728 Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases https://ClinicalTrials.gov/show/NCT00910728 Completed AstraZeneca 2012-03-31
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT01423058 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01423058 Completed Sierra Oncology, Inc. 2014-06-30
NCT00807677 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00807677 Completed Millennium Pharmaceuticals, Inc. 2012-09-30
NCT01787487 Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm https://ClinicalTrials.gov/show/NCT01787487 Recruiting M.D. Anderson Cancer Center 2020-07-26
NCT03935555 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib https://ClinicalTrials.gov/show/NCT03935555 Recruiting Samus Therapeutics, Inc. 2020-05-15
NCT03222609 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis https://ClinicalTrials.gov/show/NCT03222609 Recruiting AbbVie 2021-05-17
NCT00745550 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis https://ClinicalTrials.gov/show/NCT00745550 Completed S*BIO 2012-01-31
NCT00724334 A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00724334 Completed Sanofi 2014-05-31
NCT00719836 A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies https://ClinicalTrials.gov/show/NCT00719836 Completed S*BIO 2012-01-31
NCT00669578 CC-4047 in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00669578 Completed Mayo Clinic 2010-07-07
NCT00631462 A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00631462 Completed TargeGen 2009-10-31
NCT00611351 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00611351 Completed University of Nebraska 2008-02-29
NCT00606437 Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants https://ClinicalTrials.gov/show/NCT00606437 Completed Duke University 2014-02-28
NCT00599547 Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT00599547 Completed Universitätsklinikum Hamburg-Eppendorf 2009-08-31
NCT00589563 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer https://ClinicalTrials.gov/show/NCT00589563 Completed City of Hope Medical Center 2012-02-29
NCT00572897 Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis https://ClinicalTrials.gov/show/NCT00572897 Completed Icahn School of Medicine at Mount Sinai 2011-08-31
NCT00572065 Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00572065 Completed Weill Medical College of Cornell University 2009-12-31
NCT00569660 Ph II Study of Azacitidine in Myelofibrosis https://ClinicalTrials.gov/show/NCT00569660 Completed M.D. Anderson Cancer Center 2008-04-30
NCT00509899 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT00509899 Completed Incyte Corporation 2007-12-31
NCT00506402 A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00506402 Completed CASI Pharmaceuticals, Inc. 2009-01-31
NCT00494585 CEP-701 for PH-negative Myelofibrosis https://ClinicalTrials.gov/show/NCT00494585 Completed M.D. Anderson Cancer Center 2010-05-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00475020 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00475020 Completed M.D. Anderson Cancer Center 2017-10-04
NCT00463385 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00463385 Completed Celgene 2009-05-01
NCT00445900 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00445900 Completed Mayo Clinic 2006-10-31
NCT00445744 Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00445744 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00438958 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases https://ClinicalTrials.gov/show/NCT00438958 Completed National Cancer Institute (NCI) NA
NCT00424242 Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases https://ClinicalTrials.gov/show/NCT00424242 Active, not recruiting Northwestern University 2020-03-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00397813 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00397813 Completed Fred Hutchinson Cancer Research Center 2017-09-30
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00381550 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00381550 Completed National Cancer Institute (NCI) 2011-03-31
NCT00360035 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00360035 Completed Teva Pharmaceutical Industries 2008-03-31
NCT00357305 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00357305 Completed National Cancer Institute (NCI) 2011-11-30
NCT00352794 Lenalidomide for Patients With Myelofibrosis (MF) https://ClinicalTrials.gov/show/NCT00352794 Completed M.D. Anderson Cancer Center 2018-03-08
NCT00351975 Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases https://ClinicalTrials.gov/show/NCT00351975 Completed National Cancer Institute (NCI) 2013-03-31
NCT00309842 Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases https://ClinicalTrials.gov/show/NCT00309842 Completed Masonic Cancer Center, University of Minnesota 2019-07-29
NCT00287261 A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) https://ClinicalTrials.gov/show/NCT00287261 Completed Universitaire Ziekenhuizen Leuven 2008-03-31
NCT00274820 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder https://ClinicalTrials.gov/show/NCT00274820 Completed Case Comprehensive Cancer Center 2007-09-30
NCT00255346 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) https://ClinicalTrials.gov/show/NCT00255346 Completed M.D. Anderson Cancer Center 2017-03-03
NCT00235391 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload https://ClinicalTrials.gov/show/NCT00235391 Completed Novartis 2008-10-31
NCT00227591 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00227591 Completed National Cancer Institute (NCI) 2010-12-31
NCT00136409 A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) https://ClinicalTrials.gov/show/NCT00136409 Completed Dana-Farber Cancer Institute 2005-08-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00095784 Decitabine in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00095784 Active, not recruiting National Cancer Institute (NCI) 2008-07-01
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00088231 PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP https://ClinicalTrials.gov/show/NCT00088231 Completed M.D. Anderson Cancer Center 2006-10-31
NCT00087672 A Phase II Study of CC-5013 in Myelofibrosis https://ClinicalTrials.gov/show/NCT00087672 Completed M.D. Anderson Cancer Center 2009-02-28
NCT00086125 Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) https://ClinicalTrials.gov/show/NCT00086125 Completed Merck Sharp & Dohme Corp. 2006-06-30
NCT00006367 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00006367 Completed Fred Hutchinson Cancer Research Center NA
NCT00015821 Thalidomide in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00015821 Completed National Cancer Institute (NCI) 2007-12-31
NCT00047190 Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00047190 Completed National Cancer Institute (NCI) 2007-04-30
NCT00039416 Imatinib Mesylate in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00039416 Completed National Cancer Institute (NCI) 2007-08-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00081874 RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00081874 Completed M.D. Anderson Cancer Center 2006-09-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03208803 Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis https://ClinicalTrials.gov/show/NCT03208803 Active, not recruiting Centre Hospitalier Annecy Genevois 2017-12-30
NCT02953704 Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) https://ClinicalTrials.gov/show/NCT02953704 Active, not recruiting Incyte Corporation 2022-03-31
NCT02934477 Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT02934477 Recruiting Center for International Blood and Marrow Transplant Research 2026-11-30
NCT02910258 Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis https://ClinicalTrials.gov/show/NCT02910258 Completed University Hospital, Brest 2017-03-31
NCT02897297 Myeloproliferative Neoplastic Diseases Observatory From Brest https://ClinicalTrials.gov/show/NCT02897297 Recruiting University Hospital, Brest 2025-09-30
NCT01956799 Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy https://ClinicalTrials.gov/show/NCT01956799 Active, not recruiting Fondazione Italiana Sindromi Mielodisplastiche Onlus 2018-07-31
NCT04282421 Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France https://ClinicalTrials.gov/show/NCT04282421 Completed Central Hospital, Nancy, France 2017-12-31
NCT04153305 European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study https://ClinicalTrials.gov/show/NCT04153305 Recruiting Fondazione per la Ricerca Ospedale Maggiore 2021-05-31
NCT03959371 Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy https://ClinicalTrials.gov/show/NCT03959371 Recruiting Ospedale di Circolo - Fondazione Macchi 2021-12-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT00723333 Bone Marrow Transplant Chart Review for RIC https://ClinicalTrials.gov/show/NCT00723333 Completed University of Utah 2009-07-31
NCT00715247 Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes https://ClinicalTrials.gov/show/NCT00715247 Completed University of Utah 2018-12-31
NCT00666549 Research Tissue Bank https://ClinicalTrials.gov/show/NCT00666549 Completed Icahn School of Medicine at Mount Sinai 2017-03-27
NCT00666289 Familial Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00666289 Completed Icahn School of Medicine at Mount Sinai 2015-01-20
NCT00665067 Correlative Biomarker Study in Patients With Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00665067 Completed Icahn School of Medicine at Mount Sinai 2018-07-20
NCT00433862 Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00433862 Completed National Institutes of Health Clinical Center (CC) NA
NCT00069680 Genetic Analysis of Gray Platelet Syndrome https://ClinicalTrials.gov/show/NCT00069680 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31